SCHEMBL16731670

SCHEMBL16731670

O=C(O)c1cccc(C#Cc2nccs2)c1-c1cnc2ccccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM5 P41594 1/20 0.40
▸ MGAM O43451 1/20 0.39
▸ MAP4K4 O95819 1/20 0.38
▸ CSNK1G2 P78368 1/20 0.38
▸ CLK4 Q9HAZ1 1/20 0.38
▸ MKNK2 Q9HBH9 1/20 0.38
▸ MAP4K5 Q9Y4K4 1/20 0.38
▸ CYP1A2 P05177 1/20 0.37
▸ PDGFRB P09619 2/20 0.37
▸ PDGFRA P16234 2/20 0.37
▸ HAO1 Q9UJM8 1/20 0.36
▸ MCL1 Q07820 1/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ PIK3CB P42338 1/20 0.36
▸ PIK3CG P48736 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ CNR1 P21554 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16720297 0.84 MGAM (0.45) MGAMMAP4K4CSNK1G2CLK4MKNK2
SCHEMBL20011693 0.82 GRM5 (0.36) GRM5MAP4K4CSNK1G2CLK4MKNK2
SCHEMBL16731649 0.80 GRM5 (0.43) GRM5CYP1A2HAO1HPGD
SCHEMBL16719454 0.80 GRM5 (0.40) GRM5MGAMMAP4K4CSNK1G2CLK4
SCHEMBL18125279 0.79 MAP4K4 (0.42) MGAMMAP4K4CSNK1G2CLK4MKNK2
SCHEMBL16719363 0.79 MGAM (0.40) MGAMMAP4K4CSNK1G2CLK4MKNK2
SCHEMBL18125281 0.79 CTSA (0.43) GRM5CYP1A2HAO1MCL1MAPT
SCHEMBL16731663 0.77 NPC1 (0.40) GRM5MAP4K4CLK4MAP4K5HAO1
SCHEMBL16731648 0.77 HSD11B1 (0.39) GRM5CLK4CYP1A2HAO1PIK3CD
SCHEMBL16720170 0.77 ALDH1A1 (0.43) MGAMMAP4K4CSNK1G2CLK4MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220396551-A1 EBNA1 Inhibitors and Their Method of Use WISTAR INST (US) 2022-12-15 — — US disclosed
US-11242317-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2022-02-08 — — US disclosed
EP-3068758-B1 EBNA1 INHIBITORS AND THEIR METHOD OF USE WISTAR INST (US) 2021-09-08 — — EP disclosed
US-20200181078-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE WISTAR INST (US) 2020-06-11 — — US disclosed
US-10421718-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2019-09-24 — — US disclosed
US-20180086699-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-03-29 — — US disclosed
US-20180086699-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-03-29 — — US disclosed
US-9856214-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2018-01-02 — — US disclosed
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-10-06 — — US disclosed
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-10-06 — — US disclosed
WO-2015073864-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2015-05-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11242317-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML GRM5 3225/4885MGAM 2695/4885MAP4K4 3062/4885
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE MCM5, EBNA1BP2, MLLT1 GRM5 3154/4885MGAM 2470/4885MAP4K4 2536/4885
US-20200181078-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE EBNA1BP2, MLLT1, PML GRM5 3225/4885MGAM 2695/4885MAP4K4 3062/4885
US-10421718-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML GRM5 3225/4885MGAM 2695/4885MAP4K4 3062/4885
US-20180086699-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE EBNA1BP2, MLLT1, PML GRM5 3225/4885MGAM 2695/4885MAP4K4 3062/4885
US-20220396551-A1 EBNA1 Inhibitors and Their Method of Use EBNA1BP2, MLLT1, PML GRM5 3225/4885MGAM 2695/4885MAP4K4 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback